RFK Jr., a prominent vaccine skeptic, wants to make many changes to the U.S. food and drug system as head of the HHS. Here's ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

The Stoxx Europe 600 Index swelled 1.5% to 517.07. Related NewsInflation Rate YoY for Oct in United States is 2.6%, higher ...

COPENHAGEN (Reuters) - Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply in that market, its CEO said on Wednesday.

Both Ozempic and Wegovy are forms of semaglutide, a GLP-1 agonist drug manufactured by Novo Nordisk ... demand for semaglutide within the United States exceeds the available supply.

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have now been linked to at least ...

“For example, your company charges $969 in the United States for one month of Ozempic but just $155 in Canada and just $59 in Germany,” Sanders wrote. While Novo Nordisk pushes for a ban on ...

Novo Nordisk’ chief executive Lars Fruergaard Jørgensen has agreed to appear at a Senate hearing later this year to defend the pricing of the group’s semaglutide-based therapies for diabetes ...

"Please tell me why you think it is appropriate to charge Americans nine times more for the same exact product that you sell in Germany," asked Senate ... as Novo Nordisk CEO Lars Jergensen ...

(Image Credits: Pixabay) Novo Nordisk said on Monday an oral version ... Novo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of ...

Kennedy has criticized the popular Novo Nordisk NOVOb.CO drug Ozempic, which is often prescribed for weight loss, saying it ...